Olmutinib
45-16 Ramsey Road Shirley, NY 11967, USA, New York, New York, 11967
About us
Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). https://www.bocsci.com/olmutinib-cas-1353550-13-6-item-470842.html
Is this your business?
Featured businesses
604 3rd ave, New York, New York, 10016
(347) 559-0871
110 Chambers Street, New York, New York, 10007
(212) 933-4737